2025 · 3rd Quarter (July 1 - Sep 30)

ELI LILLY & COMPANY

Filed by WILLIAMS AND JENSEN, PLLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2025
Income: $50,000.00
Expenses: Not reported
Registrant: WILLIAMS AND JENSEN, PLLC
Client: ELI LILLY & COMPANY
Filing UUID: 8cf0bb4c-5305-4f16-b55b-89c265665abf
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

DEF · Defense

Issues related to pharmaceutical manufacturing and development.

PHA · Pharmacy

Drug importation, prescription drug safety, value and access.

MMM · Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Literal federal measure citations: H.R. 4818, S. 2407

BUD · Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

TRD · Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

TAX · Taxation/Internal Revenue Code

International and domestic tax issues. H.R. 1, One Big Beautiful Bill Act implementation.

Literal federal measure citations: H.R. 1

HCR · Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.